DARPA efforts tweak tobacco-based vax making

The Defense Advanced Research Projects Agency is funding four efforts to develop vaccine manufacturing processes based on fast-growing tobacco plants. Under its Blue Angel initiative, begun in May 2009, the agency assigned four companies to the task.

The companies are Fraunhofer USA Center for Molecular Biotechnology in Delaware; Kentucky Bioprocessing in Owensboro; a consortium called Project GreenVax, whose partners are the Texas A&M University system and a Texas company called G-Con; and Medicago in North Carolina.

Each is developing its own variation on the tobacco theme. Such details as how plants are infected, the kinds of vectors used, and how the protein is purified are where the approaches differ. And the projects are at different stages. Fraunhofer, for example, already has a product in Phase I testing.

Another Blue Angel project is Modular Immune In Vitro Constructs, which aims to quickly test new vaccines for safety and effectiveness. VaxDesign Corp. has developed a technology for mixing human immune cells and biological molecules for use in predicting dosing, dose timing and cross-protection against other viral strains. The goal is to minimize or eliminate lengthy and costly clinical testing.

- here's the article


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.